Patient JourneyFAQsClinical StudiesPost-Procedure InstructionsTestimonialsContact

Stem Cell Therapy for Diabetes

GMP-expanded Wharton's jelly mesenchymal stem cells for Type 1 and Type 2 diabetes — adjunctive immunomodulation, β-cell signaling support, and metabolic inflammation modulation at our Istanbul clinic.

Living with Type 1 or Type 2 diabetes?

Share your diagnosis type, duration, and recent HbA1c — our Istanbul endocrinology team will return an honest, written candidacy assessment within 24 hours.

Request Free Diabetes AssessmentWhatsApp Us

MSC Therapy for Diabetes — An Honest Overview

Stem cell therapy is not a cure for diabetes, and we will never tell you otherwise. What the published evidence does support is a meaningful adjunctive role for mesenchymal stem cell (MSC) therapy in both Type 1 and Type 2 diabetes — particularly when started early, combined with continued medical management, and delivered with documented GMP-grade dosing.

At TurkeyStemcell we use allogeneic Wharton's jelly umbilical cord MSCs — the most potent source of mesenchymal cells for immunomodulation and metabolic signaling. Every dose is expanded under cGMP conditions in an ISO-accredited Istanbul facility and released only after a full panel of viability, identity, sterility, endotoxin, and mycoplasma testing.

Treatment is delivered by IV infusion, sometimes combined with MSC-derived exosome adjuncts for neuropathy or microvascular indications. The complete protocol is finished during a single 3–5 day visit, with 12 months of remote follow-up tracking your glycemic and inflammatory markers.

How MSCs Work in Diabetes

Four documented mechanisms — each addressed by Type 1 and Type 2 protocols at our Istanbul clinic.

Immune modulation (Type 1)

MSCs downregulate the autoreactive T-cells that destroy pancreatic β-cells in Type 1 diabetes, helping preserve residual insulin-producing capacity.

Insulin sensitivity (Type 2)

MSC-secreted anti-inflammatory cytokines reduce chronic low-grade inflammation that drives peripheral insulin resistance in Type 2 diabetes.

β-cell signaling support

Paracrine growth factors (HGF, IGF-1, VEGF) support β-cell survival and may signal endogenous regeneration of insulin-secreting cells.

Diabetic complication support

Documented improvements in diabetic neuropathy pain, microvascular function, and wound healing — frequently co-treated alongside glycemic protocols.

Diabetes Programs at TurkeyStemcell

Three standardized diabetes protocols. The right one depends on diagnosis type, disease duration, and presence of complications.

ProgramDoseDurationGoals
Type 1 Diabetes Adjunctive Protocol2 × 100M Wharton's jelly UC-MSCs IV3–5 day visitPreserve residual β-cell function, reduce daily insulin requirement, stabilize HbA1c. Best results in patients within 2–5 years of diagnosis.
Type 2 Diabetes Metabolic Protocol1–2 × 100M UC-MSCs IV + exosome adjunct3 day visitImprove insulin sensitivity, reduce inflammatory markers, support weight and lipid profile in combination with lifestyle protocol.
Diabetic Neuropathy Protocol100M IV MSCs + targeted exosomes3–4 day visitAddress microvascular dysfunction and small-fiber nerve damage; complements standard pain management.

Who Is a Good Candidate?

  • Type 1 patients within 5 years of diagnosis with detectable C-peptide.
  • Type 2 patients with elevated inflammatory markers, recent diagnosis, or insulin-resistance phenotype.
  • Patients with diabetic neuropathy or microvascular complications seeking regenerative adjunct.
  • Patients willing to maintain medical management of glycemia alongside MSC therapy.

We do not promise insulin independence, cure, or any specific HbA1c result. Long-standing Type 1 diabetes with no residual β-cell function is unlikely to respond meaningfully — we will tell you that honestly during consultation. Active malignancy, severe infection, and pregnancy are contraindications.

Frequently Asked Questions

No. Stem cell therapy is not a cure for either Type 1 or Type 2 diabetes, and we do not promise insulin independence. Published evidence does support a meaningful adjunctive role: mesenchymal stem cell (MSC) therapy may help preserve residual β-cell function in early Type 1 diabetes, improve insulin sensitivity in Type 2 diabetes, and reduce inflammatory and microvascular complications. Patients continue to require medical management of glycemia.

Both Type 1 and Type 2 diabetes can be assessed. Type 1 patients within 5 years of diagnosis with detectable C-peptide tend to show the strongest response. Type 2 patients with elevated inflammatory markers, recent diagnosis, or diabetic complications (neuropathy, early nephropathy) are also good candidates. Long-standing Type 1 with no residual β-cell function is unlikely to benefit and we will say so honestly during consultation.

We use allogeneic Wharton's jelly umbilical cord mesenchymal stem cells (UC-MSCs) — the most potent MSC source for immunomodulation and anti-inflammatory signaling. Every dose is GMP-expanded and released only after viability, surface marker, sterility, endotoxin, and mycoplasma testing. You receive documentation of the exact cell count and viability of your batch.

Treatment is delivered primarily by IV infusion in our Istanbul clinic, sometimes combined with MSC-derived exosome IV adjuncts. There is no surgery, no liposuction, no bone-marrow aspiration. The IV takes 60–90 minutes per session, and the full protocol is completed during a 3–5 day visit.

Published Type 1 outcomes show preservation of C-peptide, modest reduction in daily insulin requirement, and improved HbA1c stability in 50–70% of treated patients within 6–12 months — best in early-disease patients. Type 2 outcomes typically include 1.0–1.5 percentage-point HbA1c reduction, improved insulin sensitivity, and inflammatory marker improvement. We do not promise insulin independence or cure — outcomes vary by disease type, duration, and baseline function.

No — we do not make that claim and you should be skeptical of any clinic that does. MSC therapy may reduce insulin requirements in some Type 1 patients with preserved C-peptide, but complete insulin independence is rare and unpredictable. Realistic goals are better glycemic stability, reduced complication risk, and improved quality of life. We will not promise outcomes we cannot deliver.

Yes. UC-MSC therapy has an excellent published safety profile across more than 1,000 clinical studies, including diabetes-specific trials. Side effects are uncommon and typically limited to mild transient fatigue or low-grade fever in the 24 hours after infusion. There are no documented graft-versus-host risks with allogeneic MSCs because these cells are immune-privileged.

Diabetes protocols at TurkeyStemcell range from $8,500 to $16,000 depending on number of IV sessions, exosome adjuncts, and inclusion of neuropathy-specific protocols. This includes the full medical protocol, hospital fees, hotel accommodation, airport transfers, and concierge support. Comparable US/EU pricing typically ranges from $30,000 to $80,000.

Most diabetes protocols are completed in 3–5 days. Patients fly home with a 12-month follow-up plan and remote support from our medical team for ongoing glycemic and inflammatory marker tracking.

Discuss Your Diabetes Profile with a Specialist

Share your diagnosis type, duration, recent HbA1c, and current medications. Our medical team will give you an honest assessment of candidacy and a personalized protocol plan.

Request a Free Diabetes ConsultationWhatsApp Us

Or call directly: +90 534 856 92 92